Citius Pharmaceuticals
CTXRCitius Pharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing first-in-class critical care products, primarily in oncology and anti-infectives.
Table of contents
Earnings
Next report
Aug 11, 2026 (in a month)Competitors
By market cap
Profile
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on developing and commercializing first-in-class critical care products, primarily in oncology and anti-infectives. The company specializes in creating new formulations of previously approved drugs to reduce development risk while addressing unmet medical needs in underserved markets. Its portfolio includes an FDA-approved immunotherapy for cutaneous T-cell lymphoma and late-stage candidates for catheter-related infections and hemorrhoids.
Citius positions itself as a developer of lower-risk 'first-in-class' products by reformulating known entities with established safety data to fill gaps where no FDA-approved alternatives exist.
Questions, answered.
- What is Citius Pharmaceuticals's market cap?
- Citius Pharmaceuticals (CTXR) has a market capitalization of $15.4M and trades on NASDAQ.
- Who are Citius Pharmaceuticals's competitors?
- Citius Pharmaceuticals's key competitors include CorMedix Inc., Merck & Co., Mesoblast Limited, and others. These companies compete in similar markets and product categories.
- Who does Citius Pharmaceuticals partner with?
- Citius Pharmaceuticals's notable partners include Eisai Co., Ltd., Dr. Reddy’s Laboratories, Cardinal Health, and others.
- What subsidiaries does Citius Pharmaceuticals have?
- Citius Pharmaceuticals's subsidiaries include Citius Oncology, Inc., NoveCite, Inc., Leonard-Meron Biosciences, Inc..
- Where is Citius Pharmaceuticals headquartered?
- Citius Pharmaceuticals is headquartered in United States of America and employs approximately 22 people. It has been publicly traded since 2011.